Repare Therapeutics Inc
NASDAQ:RPTX

Watchlist Manager
Repare Therapeutics Inc Logo
Repare Therapeutics Inc
NASDAQ:RPTX
Watchlist
Price: 2.81 USD -5.39% Market Closed
Market Cap: 119.5m USD
Have any thoughts about
Repare Therapeutics Inc?
Write Note

Net Margin
Repare Therapeutics Inc

-183.4%
Current
-7 873%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-183.4%
=
Net Income
-93.8m
/
Revenue
51.1m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CA
Repare Therapeutics Inc
NASDAQ:RPTX
118.5m USD
-183%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
9%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
133.6B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.8B EUR
-14%
Country CA
Market Cap 118.5m USD
Net Margin
-183%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 312.7B USD
Net Margin
9%
Country US
Market Cap 158.3B USD
Net Margin
13%
Country US
Market Cap 116.2B USD
Net Margin
-5%
Country US
Market Cap 112.4B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 133.6B AUD
Net Margin
18%
Country US
Market Cap 81.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.8B EUR
Net Margin
-14%
No Stocks Found

Repare Therapeutics Inc
Glance View

Market Cap
118.5m USD
Industry
Biotechnology

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 152 full-time employees. The company went IPO on 2020-06-19. The firm is focused on the development of synthetic lethality (SL) based therapies to patients with cancer. The company uses genome wide, SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The firm is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated (ATM) kinase gene. Its preclinical programs include RP-6306 Protein Kinase Membrane-associated tYrosine- and Threonine- specific cdc-2 inhibitory (PKMYT1)kinase SL inhibitor, in advanced solid tumors.

RPTX Intrinsic Value
4.08 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-183.4%
=
Net Income
-93.8m
/
Revenue
51.1m
What is the Net Margin of Repare Therapeutics Inc?

Based on Repare Therapeutics Inc's most recent financial statements, the company has Net Margin of -183.4%.